Articles related to TARGETED THERAPIES

Radiopharmaceuticals represent a burgeoning frontier in cancer treatment, offering targeted therapies that minimize collateral damage to healthy tissues.

In a recent phase 3 trial, alectinib has shown a notable improvement in both disease-free and CNS disease-free survival in patients with ALK-positive NSCLC, indicating a robust alternative to platinum-based chemotherapy regimens.

Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.

In a recent phase 3 trial, the addition of brentuximab vedotin to standard chemotherapy not only achieved a notable improvement in 3-year event-free survival rates for pediatric Hodgkin’s lymphoma patients but also maintained a comparable safety profile, underscoring the therapeutic potential of targeted treatments in this population.

The AHS’s new consensus underscores the pivotal role of CGRP-targeting therapies in migraine prevention, marking a key advancement in patient care. These treatments offer a focused approach, approved for both episodic and chronic migraine, setting a new standard in therapeutic strategies.

Explore the latest findings on vibecotamab’s potential in R/R AML treatment, revealing promising results with an optimized dosing regimen that mitigates cytokine response syndrome while improving patient outcomes.